#United States #San Diego #Class Action #Robbins LLP #Altimmune

Overview

On August 14, 2025, Robbins LLP announced the initiation of a class action lawsuit concerning Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical firm known for developing therapies targeting obesity, metabolic, and liver disorders. This lawsuit has been filed on behalf of shareholders who acquired Altimmune securities from August 10, 2023, to June 25, 2025.

The Allegations

The lawsuit revolves around claims that Altimmune misled its investors regarding the success of its IMPACT Phase 2b trial for Pemvidutide, aimed at treating Metabolic Dysfunction-associated Steatotic Liver Disease (MASH). During the period in question, the company’s executives reportedly made overly optimistic statements about the expected outcomes of this clinical trial. However, on June 26, 2025, it was disclosed that the trial results did not yield the anticipated statistical significance, primarily due to higher than expected responses from the placebo group. Following this announcement, Altimmune's stock plummeted by more than 53%, falling from $7.71 per share to $3.61 within just one day.

Implications for Shareholders

Affected investors are being encouraged to reach out to Robbins LLP for further information regarding their eligibility to join the class action. The lead plaintiff designation is particularly important as it represents the larger group in guiding the litigation process. Interested shareholders must submit their documentation to the court no later than October 6, 2025. Notably, shareholders are not obligated to partake in the legal proceedings to potentially receive any financial recovery; they can elect to remain as absent class members.

Legal Representation and Potential Outcomes

Robbins LLP operates on a contingency basis, meaning that shareholders involved in the lawsuit will not incur any legal fees unless they recover funds. This business model underscores the firm’s commitment to helping investors recover losses stemming from corporate misconduct. Since its foundation in 2002, Robbins LLP has built a reputation as a leader in shareholder rights litigation, dedicated to ensuring that corporate executives are held accountable.

Contact Information

For those interested in learning more about the class action or signing up for alerts regarding this case, share owners should contact Aaron Dumas, Jr. at Robbins LLP, located at 5060 Shoreham Place, Suite 300, San Diego, CA 92122. They can also reach him via email at [email protected] or by calling (800) 350-6003.

Conclusion

The ongoing legal fight can offer a semblance of justice and recompense for those shareholders who feel they have been wronged by Altimmune's disclosures. As the case progresses, updates will be critical in determining the financial and corporate accountability landscape for investors in this sector. Those affected should act swiftly and seek the necessary legal guidance to navigate this complicated process.